Efficacy of coronary artery calcification on Denosumab

Comparison study to evaluate the effect of denosumab or alendronate sodium hydrate on coronary artery calcification score for osteoporosis with complications of coronary artery disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031190025

Enrollment

108

Registered

2019-05-20

Start date

2019-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with osteoporosis with coronary artery calcification osteoporosis, coronary artery calcification

Interventions

Denosumab group 60mg once every 6 months, subcutaneously. Arendronate sodium hydrate group 35mg orally once a week with approximately 180mL of water at the time of getting up in the morning.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients (>20 years old) with osteoporosis with coronary artery calcification

Exclusion criteria

Exclusion criteria: Patients who can not enforce coronary artery CT, patients with baseline coronary calcification score of 0 or 1000 or more, secondary osteoporosis patients, patients with severe renal impairment(eGFR<35mL/min).

Design outcomes

Primary

Measure	Time frame
Percent change in coronary artery calcification score at 48 weeks after intervention	—

Secondary

Measure	Time frame
Degree of improvement of bone density by DXA at 48 weeks after intervention Percent change in coronary volume score at 48 weeks after intervention	—

Contacts

Public ContactNaoki Kubota

Niigata University Medical and Dental Hospital

naoki_kub@yahoo.co.jp+81-25-227-2185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026